{"id":2581,"date":"2020-10-27T00:00:00","date_gmt":"2021-03-18T01:05:10","guid":{"rendered":"https:\/\/www.eisai.com.cn\/?p=2581"},"modified":"2021-03-18T09:05:10","modified_gmt":"2021-03-18T01:05:10","slug":"global-coalition-for-adaptive-research-amgen-and-eisai-announce-first-patient-enrolled-in-international-covid-19-trial","status":"publish","type":"post","link":"https:\/\/www.eisai.com.cn\/en\/2020\/10\/27\/global-coalition-for-adaptive-research-amgen-and-eisai-announce-first-patient-enrolled-in-international-covid-19-trial\/","title":{"rendered":"GLOBAL COALITION FOR ADAPTIVE RESEARCH, AMGEN, AND EISAI ANNOUNCE FIRST PATIENT ENROLLED IN INTERNATIONAL COVID-19 TRIAL"},"content":{"rendered":"

AMGEN AND EISAI TO PARTICIPATE IN THE IMMUNE MODULATION DOMAIN OF REMAP-COVID, AN ADAPTIVE CLINICAL TRIAL TO TEST INTERVENTIONS FOR PATIENTS HOSPITALIZED WITH COVID-19<\/p>\n

AMGEN\u2019S APREMILAST AND EISAI\u2019S ERITORAN TO BE EVALUATED ACROSS MULTIPLE INTERNATIONAL TRIAL SITES WITHIN THE REMAP NETWORK<\/em><\/p>\n

(BUSINESS WIRE)–Global Coalition for Adaptive Research (LOS ANGELES, CA), Amgen (THOUSAND OAKS, CA),\u00a0and Eisai Co., Ltd. (TOKYO, Japan “Eisai”) — The Global Coalition for Adaptive Research (GCAR) in collaboration with Amgen and Eisai, today announced enrollment of the first patient in the immune modulation domain of REMAP-COVID, a sub-study of REMAP-CAP (A\u00a0R<\/u>andomized,\u00a0E<\/u>mbedded,\u00a0M<\/u>ultifactorial,\u00a0A<\/u>daptive\u00a0P<\/u>latform trial for\u00a0C<\/u>ommunity-A<\/u>cquired\u00a0P<\/u>neumonia) that tests multiple interventions for the treatment of patients hospitalized with COVID-19. Amgen\u2019s\u00a0apremilast<\/em>\u00a0and Eisai\u2019s investigational\u00a0eritoran<\/em>\u00a0are being evaluated as potential therapeutic agents.<\/p>\n

REMAP-CAP was developed to test treatments for severe pneumonia both in non-pandemic and pandemic settings. In February 2020, REMAP-CAP rapidly pivoted to its pandemic mode (the REMAP-COVID sub-study), as per its original intent, to incorporate additional potential treatment regimens specifically targeting COVID-19 and to expand enrollment to COVID-19 patients. This trial is a multicenter, randomized platform study, with treatments tested within groupings or “domains” based on pathway or mechanism of action.<\/p>\n

The trial is being conducted in the multi-hospital UPMC (University of Pittsburgh Medical Center) health system along with over 20 hospitals in the United States. Additional global sites across the trial network will follow. University of Pittsburgh is serving as the U.S. Regional Coordinating Center.<\/p>\n

“Partnering with the biopharmaceutical industry to be able to efficiently test well-understood targeted agents is critical to understanding treatment paradigms for COVID-19 patients,” says Derek Angus, MD., MPH, FRCP, U.S. Principal Investigator of REMAP and Chief Healthcare Innovation Officer, UPMC Health System. “Today\u2019s announcement marks an important milestone in the collaboration between industry and the scientific and academic community to work collectively to evaluate potentially promising therapies to support patients hospitalized with COVID-19.”<\/p>\n

Amgen\u2019s\u00a0apremilast<\/em>\u00a0is an oral drug which inhibits the activity of PDE4 (Phosphodiesterase 4), an enzyme found in inflammatory cells in the human body. By inhibiting PDE4,\u00a0apremilast<\/em>\u00a0is thought to modulate the production of inflammatory cytokines and other mediators, which may prove helpful in inhibiting the inflammatory response associated with the signs, symptoms and pulmonary involvements observed in some COVID-19 patients.\u00a0Apremilast<\/em>\u00a0is currently approved for use in more than 45 countries as an oral treatment for inflammatory diseases including moderate to severe plaque psoriasis, psoriatic arthritis and oral ulcers associated with Behcet\u2019s disease.<\/p>\n

“Amgen believes that, based on its mechanism of action,\u00a0apremilast<\/em>\u00a0might help prevent the respiratory distress seen in moderate to severe-stage adult COVID-19 patients,” said David M. Reese, M.D., Executive Vice President of Research and Development at Amgen. “We are proud to be joining REMAP-COVID, which is an important and innovative effort utilizing a platform approach and has the\u00a0potential to rapidly identify whether\u00a0apremilast<\/em>\u00a0may improve health outcomes for patients hospitalized with moderate to severe COVID-19.”<\/p>\n

Eritoran\u00a0<\/em>is Eisai\u2019s in-house discovered and developed investigational TLR4 (Toll-Like Receptor 4) antagonist created with natural product organic synthesis technology. It is a structural analogue of Lipid A, which is an activator of endotoxins of bacteria. It has been previously observed to be safe in 14 clinical studies including a large Phase 3 randomized trial in severe sepsis. It is expected to suppress inflammation and increasing in severity caused by COVID-19 by inhibiting the activation of TLR4, which is found in the most upstream of various cytokine gene expression signaling that causes the cytokine-storm.<\/p>\n

“Eisai is pleased to participate in the groundbreaking REMAP-COVID effort, and we expect that this study will generate important insights about\u00a0eritoran\u2019s<\/em>\u00a0potential to possibly improve health outcomes for patients with moderate and severe COVID-19,” said Lynn Kramer, M.D., FAAN, Chief Clinical Officer, Neurology Business Group, Eisai “As part of our human health care mission, we are committed to making a difference for patients, their families and health care professionals across the globe.”<\/p>\n

GCAR is the U.S. Sponsor of REMAP-COVID and is guiding efforts to facilitate the inclusion of multiple pharma partners in REMAP-COVID globally.<\/p>\n

“GCAR is delighted to utilize our expertise in implementing and overseeing innovative trials to collaborate on this important effort,” shared Meredith Buxton, PhD, Chief Executive Officer of GCAR.\u00a0 “We are committed to working closely with pharma and the REMAP Network to identify new effective treatments for patients with COVID-19 by serving as U.S. sponsor of this important and innovative platform trial.<\/p>\n

\nAbout REMAP-CAP<\/strong><\/p>\n

REMAP-CAP is led by world experts in critical care, clinical trials, pandemic and infectious disease outbreaks, virology, immunology, emergency medicine, and Bayesian statistics. REMAP-CAP has enrolled over 2000 patients at 263 sites across 19 countries. This vital research is being conducted in collaboration with Berry Consultants, leaders in statistical design for adaptive platform trials, and is being supported by governments and non-profits worldwide.<\/p>\n

To learn more about REMAP-CAP and the REMAP-COVID sub-study, please visit\u00a0<\/em><\/strong>www.remapcap.org<\/em><\/strong><\/a>\u00a0and follow\u00a0<\/em><\/strong>@remap_cap<\/em><\/strong><\/a><\/p>\n


\n<\/strong>About Otezla\u00ae\u00a0(apremilast)<\/strong><\/p>\n

Otezla\u00ae\u00a0(apremilast) is an oral small-molecule inhibitor of phosphodiesterase 4 (PDE4) specific for cyclic adenosine monophosphate (cAMP). PDE4 inhibition results in increased intracellular cAMP levels, which is thought to indirectly modulate the production of inflammatory mediators. The specific mechanism(s) by which Otezla exerts its therapeutic action in patients is not well defined.<\/p>\n

By inhibiting PDE4, Otezla is thought to modulate the production of inflammatory cytokines and other mediators, which may prove helpful in inhibiting the inflammatory response associated with the signs, symptoms and pulmonary involvements observed in some COVID-19 patients. Amgen plans to collaborate with platform trials to investigate Otezla in treatment of hospitalized COVID-19 patients.<\/p>\n

\nOtezla\u00ae\u00a0(apremilast)\u00a0U.S.\u00a0INDICATIONS<\/strong><\/p>\n

Otezla\u00ae\u00a0(apremilast) is indicated for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.<\/p>\n

Otezla is indicated for the treatment of adult patients with active psoriatic arthritis.<\/p>\n

Otezla is indicated for the treatment of adult patients with oral ulcers associated with Beh\u00e7et\u2019s\u00a0Disease.<\/p>\n


\nOtezla\u00ae\u00a0(apremilast)\u00a0U.S.\u00a0IMPORTANT SAFETY INFORMATION<\/strong><\/p>\n

Contraindications<\/strong><\/p>\n